Cystectomy/methods/*mortality Humans Lymph Node Excision/methods/*mortality Lymph Nodes/surgery Lymphatic Metastasis Pelvis/pathology Postoperative Complications/etiology Prognosis Randomized Controlled Trials as Topic Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/pathology/*surgery

Carcinoma in Situ/diagnosis/epidemiology/*pathology/surgery *Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Survival Analysis Treatment Outcome Ureteral Neoplasms/*diagnosis/epidemiology/pathology/secondary Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/*pathology/surgery

Body mass index diet dietary supplements prognosis urinary bladder cancer

Urinary bladder cancer characteristics prognosis review conflicts of interest with respect to the research authorship and/or publication of this article.

Databases Factual Disease-Free Survival Humans Lymphocytes/*cytology/immunology Neoplasm Metastasis Neutrophils/*cytology/immunology Odds Ratio Prognosis Proportional Hazards Models Risk Assessment Survival Rate Urinary Bladder Neoplasms/immunology/mortality/*pathology Urologic Neoplasms/immunology/mortality/*pathology Bladder cancer Metastatic unresectable urothelial carcinoma Neutrophil-Lymphocyte ratio Unresectable urothelial carcinoma

Biomarkers Tumor/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/*urine Biomarker Bladder cancer Diagnosis Systematic review Urine

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Cisplatin/administration & dosage Deoxycytidine/administration & dosage/analogs & derivatives Doxorubicin/administration & dosage Humans Methotrexate/administration & dosage Muscle Neoplasms/*drug therapy/pathology Neoplasm Invasiveness Prognosis Survival Rate Urinary Bladder Neoplasms/*drug therapy/pathology Vinblastine/administration & dosage Gemcitabine Bladder cancer and cisplatin chemotherapy doxorubicin/adriamycin gemcitabine and cisplatin methotrexate vinblastine

Pd-l1 bladder cancer meta-analysis prognosis survival

Administration Intravesical Antineoplastic Agents/*pharmacology Humans Maintenance Chemotherapy/*methods Neoplasm Invasiveness Neoplasm Recurrence Local/*prevention & control Prognosis Randomized Controlled Trials as Topic Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Chemotherapy Intravesical Maintenance

bacille Calmette-Guérin chemotherapy meta-analysis non-muscle invasive bladder cancer prognosis

bladder cancer clinicopathological characteristics lncRNA prognosis

Biomarkers Tumor/analysis Carcinoma Papillary/diagnosis/pathology Carcinoma Transitional Cell/diagnosis/pathology Humans Keratin-20/analysis/biosynthesis Prognosis Urinary Bladder Neoplasms/diagnosis/pathology Urologic Neoplasms/diagnosis/*pathology Urothelium/*pathology Cytokeratin 20 Molecular subtyping Thelial carcinoma Uro Urothelial lesions Variant histology

Adenocarcinoma/epidemiology/*pathology/surgery Cystectomy/*methods Digital Rectal Examination Humans Incidental Findings Male Neoplasm Recurrence Local/pathology Prognosis Prostate/pathology Prostate-Specific Antigen Prostatectomy/*methods Prostatic Neoplasms/epidemiology/*pathology/surgery Survival Rate Urinary Bladder Neoplasms/*surgery bladder neoplasms cystectomy prostatectomy prostatic neoplasms

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

bladder cancer circulating tumor cells (CTCs) meta-analysis prognosis urothelial cancer

Biomarkers Tumor/*urine Fibronectins/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/urine Biomarker Bladder cancer Diagnosis Meta-analysis Urine fibronectin standards of institutional and international research committee this article is based on previous published studies thus it does not contain any studies with human participants or animals. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cd147 bladder cancer clinicopathological features meta-analysis prognosis

Aged Diabetes Mellitus Type 2/complications/*drug therapy Disease Progression Disease-Free Survival Female Humans Hypoglycemic Agents/*therapeutic use Male Metformin/*therapeutic use Middle Aged Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Urinary Bladder Neoplasms/etiology/*mortality

Estrogen Receptor alpha/metabolism Estrogen Receptor beta/metabolism Female Humans Immunohistochemistry/*methods Male Prognosis Receptors Androgen/metabolism Retrospective Studies Software Urinary Bladder Neoplasms/*metabolism/pathology

*Biomarkers Tumor Disease Progression Gene Expression Humans Matrix Metalloproteinases/*genetics/metabolism Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*genetics/metabolism/*mortality/pathology bladder cancer matrix metalloproteinases meta-analysis